TriNetX EHR analysis of 16,569 vitiligo patients versus matched controls demonstrated higher rates of depression, anxiety, panic disorder, insomnia, and nonorganic sexual dysfunction, with slightly ...

Centanafadine XR 280 mg QD significantly reduced AISRS total scores at week 8 versus placebo (LS mean change -18.5 vs -12.6; treatment difference -5.87). Improvement in comorbid anxiety was ...

Zanubrutinib plus rituximab demonstrated a clinically meaningful progression-free survival advantage over bendamustine plus rituximab in previously untreated MCL, with a 43% risk reduction for ...

Broad formulary uptake includes unrestricted access via UnitedHealthcare, Express Scripts, Cigna, Optum Rx, and TRICARE, with prior authorization common among some Blue Cross plans and CVS Caremark.

FDA approved veligrotug-vvze for TED regardless of activity or duration, using a 12-week course of five IV infusions administered every three weeks. Pivotal THRIVE/THRIVE-2 trials met primary and all ...

An in-depth look at multiple myeloma treatment with a focus on bispecific antibodies. A special Managed Healthcare Executive supplement on the current treatment of multiple myeloma with an emphasis on ...

LightGBM modeling of county-level “multilevel ecology” retained both upstream forcing factors and downstream behaviors, explaining 95% of diabetes prevalence variation across more than 3,000 counties.

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Built from the experiences of patients, advocates and clinicians, a new MASH patient journey map offers a roadmap for navigating diagnosis and highlights the need for greater public understanding of ...

Reconstructed IPD meta-analysis showed chemoimmunotherapy improved OS and PFS versus PD-(L)1 monotherapy within PD-L1–high disease, with consistent findings across multiple analytic approaches and ...

This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to ...

This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable ...